GlassScriptPhysician profile
Rahul Komati
NPI 1164840906
$142,516.11
in general payments reported to CMS, 2019-2025
21 companies · $46K in 2025
The $46K reported for 2025 was more than what 97% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,630 · 2020: $2,239 · 2021: $2,781 · 2022: $13K · 2023: $31K · 2024: $44K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $12K · Food and Beverage: $8,356 · Consulting Fee: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,962.00 |
| Travel and Lodging | $12,299.19 |
| Food and Beverage | $8,355.64 |
| Consulting Fee | $756.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115,153.18 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $12,150.91 | 2020-2024 | Iluvien, Yutiq |
| Notal Vision, INC. | $2,318.82 | 2021-2022 | |
| Genentech USA, INC. | $2,099.22 | 2020-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $2,020.40 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $1,935.25 | 2019-2025 | Eylea Hd, Eylea |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,139.31 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $822.61 | 2019-2022 | |
| Abbvie INC. | $692.22 | 2022-2025 | |
| Allergan, INC. | $684.54 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $523.70 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb Americas INC. | $348.29 | 2024-2025 | Xipere, Visudyne |
| Alcon Vision LLC | $295.94 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.67 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $127.06 | 2019 | |
| Harrow Eye, LLC | $125.00 | 2025 | Iheezo, Triesence |
| Spark Therapeutics, INC. | $124.55 | 2019 | |
| Biogen, INC. | $112.46 | 2024 | Byooviz |
| Eyepoint US, INC. | $76.44 | 2021-2022 | |
| Coherus Oncology, INC. | $50.54 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Komati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.